Curis (CRIS) Competitors

Curis (NASDAQ:CRIS) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Which has more volatility & risk, CRIS or ACHV?

Curis has a beta of 3.42, suggesting that its share price is 242% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.

Does the media refer more to CRIS or ACHV?

In the previous week, Achieve Life Sciences had 1 more articles in the media than Curis. MarketBeat recorded 2 mentions for Achieve Life Sciences and 1 mentions for Curis. Achieve Life Sciences' average media sentiment score of 0.64 beat Curis' score of -0.86 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Achieve Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate CRIS or ACHV?

Curis presently has a consensus target price of $23.00, indicating a potential upside of 599.09%. Achieve Life Sciences has a consensus target price of $14.80, indicating a potential upside of 378.96%. Given Curis' higher possible upside, equities analysts clearly believe Curis is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Achieve Life Sciences	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.33

Do institutionals and insiders hold more shares of CRIS or ACHV?

30.0% of Curis shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 5.7% of Curis shares are held by company insiders. Comparatively, 2.0% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor CRIS or ACHV?

Curis received 359 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. However, 70.46% of users gave Achieve Life Sciences an outperform vote while only 67.81% of users gave Curis an outperform vote.

Company	Underperform	Outperform
Curis	Outperform Votes 693 67.81%	Underperform Votes 329 32.19%
Achieve Life Sciences	Outperform Votes 334 70.46%	Underperform Votes 140 29.54%

Is CRIS or ACHV more profitable?

Achieve Life Sciences has a net margin of 0.00% compared to Curis' net margin of -443.35%. Achieve Life Sciences' return on equity of -108.30% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-443.35%	-923.37%	-78.35%
Achieve Life Sciences	N/A	-108.30%	-65.20%

Which has preferable earnings & valuation, CRIS or ACHV?

Achieve Life Sciences has lower revenue, but higher earnings than Curis. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$10.02M	2.78	-$47.41M	-$7.81	-0.42
Achieve Life Sciences	N/A	N/A	-$29.82M	-$1.13	-2.73

Summary

Achieve Life Sciences beats Curis on 12 of the 18 factors compared between the two stocks.